Glaucoma is the leading cause of irreversible blindness worldwide, with clinical management predominantly focused on intraocular pressure (IOP) reduction. However, normal-tension glaucoma—in which optic nerve damage and visual field loss progress despite IOP within normal ranges—and the significant proportion of patients who continue to lose vision despite maximal IOP-lowering therapy indicate that IOP is a risk factor rather than the primary disease mechanism. The primary pathological event is retinal ganglion cell (RGC) death, which proceeds through four upstream mechanistic domains:
- Mitochondrial failure and NAD+ depletion
- Neuroinflammation and autoimmunity
- HPA axis dysfunction and cortisol-mediated trabecular meshwork impairment
- Autonomic nervous system dysregulation and vascular insufficiency at the optic nerve head
In this article, we’ll review the evidence base for each domain and propose an evidence-based, upstream-first clinical intervention sequence within a Systems Homeostasis framework, including the emerging cannabinoid neuroprotection data and the clinical implications of the glucocorticoid receptor-trabecular meshwork mechanism for HPA axis assessment in glaucoma presentations.
The Limitations of an IOP-Centric Model in Glaucoma
Glaucoma encompasses a group of progressive optic neuropathies characterized by optic nerve damage and corresponding visual field loss, with RGC death as the final common pathway.1 Current management across all glaucoma subtypes centers on IOP reduction—through prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors, laser trabeculoplasty, and surgical intervention—based on well-established evidence that elevated IOP is the primary modifiable risk factor.
However, the IOP-centric model has a significant limitation: it does not account for the substantial proportion of patients in whom glaucomatous progression continues despite target IOP achievement, and it does not explain normal-tension glaucoma (NTG), in which optic nerve damage occurs in the absence of statistically elevated pressure. NTG accounts for a significant proportion of glaucoma diagnoses globally and represents the majority of glaucoma cases in some East Asian populations.2
The most parsimonious explanation for these clinical observations is that IOP is a contributory risk factor to an underlying pathological process—RGC apoptosis—that is driven by multiple upstream mechanisms operating largely independent of pressure. Understanding these mechanisms expands the clinical intervention space substantially beyond IOP management.
Domain 1: Mitochondrial Failure and NAD+ Depletion
RGC axons have among the highest metabolic demands of any structure in the central nervous system. The optic nerve head—the unmyelinated zone where RGC axons exit the retina—requires exceptional mitochondrial density and continuous ATP production to maintain axonal transport, membrane potential, and synaptic function. This metabolic vulnerability is the mechanistic foundation of the mitochondrial domain in glaucoma.
Williams et al. (2017) demonstrated in an animal model that NAD+ levels in the aging retina decline significantly, rendering RGCs increasingly susceptible to IOP-related and IOP-independent stressors.3 Critically, NAD+ restoration through nicotinamide supplementation prevented RGC loss and visual dysfunction in aged animals. A subsequent human clinical pilot study demonstrated significant improvement in pattern electroretinogram (PERG) and visual evoked potential (VEP) parameters following six-month nicotinamide supplementation in glaucoma patients — direct validation of the NAD+-RGC axis as a clinically meaningful therapeutic target.
It should be noted that NAD+ precursor efficacy in the context of chronic inflammatory burden may be limited by CD38-mediated NAD+ depletion, as described in the companion article on the two-lever NAD+ model. Upstream immune/inflammatory burden should be assessed and addressed before precursor loading is introduced in patients with significant inflammatory presentation.
Citicoline (cytidine-5′-diphosphocholine, CDP-choline) has one of the most substantial evidence bases of any neuroprotective compound in glaucoma. It supports phosphatidylcholine synthesis—the primary structural phospholipid of neuronal membranes—and has been shown across multiple randomized controlled trials to produce measurable improvements in pattern electroretinogram amplitudes and visual evoked potential latencies in glaucoma patients, indicating direct RGC and optic nerve functional improvement.4 CoQ10, reduced in glaucomatous retinal tissue, provides essential electron carrier function in the mitochondrial respiratory chain and membrane-bound antioxidant protection. Alpha-lipoic acid, soluble in both aqueous and lipid environments, functions as a mitochondrial cofactor while regenerating CoQ10, glutathione, vitamin C, and vitamin E — providing amplified antioxidant coverage across multiple compartments.
Domain 2: Neuroinflammation and Autoimmunity
The contribution of neuroinflammation to RGC apoptosis in glaucoma has been increasingly recognized over the past decade. Microglial cells—the resident macrophages of the retina and central nervous system—become chronically activated under conditions of oxidative stress, IOP elevation, and ischemia. Activated microglia release pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6, as well as reactive oxygen species, that directly promote RGC apoptosis through both receptor-mediated and mitochondrial apoptotic pathways.5
An autoimmune dimension to glaucomatous neurodegeneration has gained research traction in recent years. Heat shock proteins (HSPs), molecular chaperones upregulated under cellular stress, have been proposed as autoantigens in glaucoma. Molecular mimicry between bacterial HSPs—notably from Helicobacter pylori and other gram-negative organisms—and human HSPs expressed in retinal tissue may trigger cross-reactive immune responses that target RGCs. Elevated HSP antibody titers have been demonstrated in some glaucoma patient populations, providing support for this autoimmune mechanism.
The endocannabinoid system has received renewed clinical interest in glaucoma specifically because of its neuroinflammatory and neuroprotective effects, rather than its IOP-reducing properties. CB2 receptors — expressed on retinal microglia, astrocytes, and RGCs — mediate anti-inflammatory, anti-apoptotic, and neuroprotective effects when activated. Cannabidiol (CBD) and cannabinol (CBN) have both demonstrated RGC-protective effects in preclinical models; CBN has shown particularly notable results, with published data indicating superior RGC protection relative to other cannabinoids tested. Lutein and zeaxanthin, the xanthophyll carotenoids concentrated in the macula and perifoveal retina, provide dual-mechanism retinal protection through blue light filtration and direct anti-inflammatory activity reducing pro-inflammatory cytokine expression in retinal tissue.
Citicoline has one of the most substantial evidence bases of any neuroprotective compound in glaucoma. It supports phosphatidylcholine synthesis—the primary structural phospholipid of neuronal membranes—and has been shown across multiple randomized controlled trials to produce measurable optic nerve improvements.
Domain 3: HPA Axis and Cortisol-Mediated Trabecular Meshwork Dysfunction
The mechanistic link between cortisol and IOP has been established through the well-characterized phenomenon of steroid-induced glaucoma, in which prolonged administration of corticosteroids—topical, inhaled, or systemic—produces IOP elevation through trabecular meshwork dysfunction. The pathway is mechanistically defined: glucocorticoid receptors (GRs) are expressed on trabecular meshwork cells, and GR activation by corticosteroids promotes accumulation of extracellular matrix components—fibronectin, laminin, myocilin—in the trabecular meshwork, reducing outflow facility and elevating IOP.6
The clinical extension of this mechanism to endogenous cortisol is both mechanistically coherent and understudied. A patient with chronic HPA axis dysregulation—characterized by elevated waking cortisol, dysregulated diurnal cortisol pattern, and reduced DHEA-S—is producing an internal glucocorticoid environment that is continuously activating trabecular meshwork GRs through the same pathway as exogenous corticosteroids. This is not a theoretical extrapolation; it is the expected downstream consequence of well-established GR pharmacology applied to endogenous cortisol production.
From a Systems Homeostasis clinical perspective, HPA axis assessment should be considered mechanistically indicated in glaucoma presentations, particularly in patients with inadequate IOP control despite appropriate pharmaceutical management. The Fluids-IQ SHP panel — measuring diurnal cortisol at four time points, DHEA-S, the cortisol/DHEA ratio, estradiol, progesterone, and testosterone — provides the relevant HPA terrain data. Addressing chronic cortisol elevation through HPA-targeted intervention has the potential to reduce the internal GR-activating burden on trabecular meshwork function, and represents an upstream IOP-relevant target that is entirely outside the scope of standard ophthalmological management.
Domain 4: Autonomic Nervous System and Vascular Perfusion
Ocular perfusion pressure—the difference between mean arterial pressure and IOP—determines blood flow to the optic nerve head. But the posterior ciliary arteries that supply the critical unmyelinated zone of the optic nerve are also directly regulated by autonomic tone. Sympathetic nervous system activation promotes vasospasm of these vessels, reducing perfusion pressure at the most metabolically vulnerable zone of the RGC axon independent of IOP.
The clinical profile of NTG patients provides strong circumstantial evidence for this mechanism: vascular dysregulation conditions including Raynaud’s phenomenon, migraine with aura, and cold peripheral extremities are significantly overrepresented in NTG populations relative to high-tension glaucoma populations and healthy controls.7 These conditions share a common underlying mechanism—enhanced sympathetic vasomotor tone and systemic vascular reactivity—suggesting that ANS dysregulation and impaired vascular regulation at the optic nerve head contribute substantially to NTG pathogenesis.
Magnesium has a direct mechanistic rationale in this domain as a physiological calcium channel antagonist. By reducing intracellular calcium in vascular smooth muscle, magnesium promotes vasodilation of the posterior ciliary arteries and improves optic nerve head perfusion. Celebi et al. (2003) demonstrated statistically significant improvements in Humphrey visual field indices in NTG patients receiving oral magnesium supplementation versus controls, with effects that were not attributable to IOP changes.8
Ginkgo biloba extract (EGb 761) has the most substantial evidence base of any botanical compound for vascular-mechanism glaucoma support. Quaranta et al. (2003) demonstrated in a randomized controlled trial that Ginkgo biloba extract produced significant stabilization of visual field progression in NTG patients over a 4-year follow-up period.9 Mechanisms include nitric oxide-mediated vasodilation of optic nerve head vessels, platelet-activating factor antagonism reducing platelet aggregation and microvascular obstruction, and direct antioxidant activity in retinal tissue. The combination of vascular and neuroprotective mechanisms makes it particularly well-suited to NTG presentations.
Clinical Sequencing Within the Systems Homeostasis Framework
The Systems Homeostasis framework organizes multi-domain clinical presentations by upstream signal priority rather than by direct proximity to the therapeutic target. Applied to glaucoma, this sequencing has both mechanistic and practical rationale.
The HPA axis domain is addressed first because cortisol elevation contributes directly to trabecular meshwork dysfunction (the IOP mechanism), drives NF-kB-mediated inflammatory signaling that feeds the neuroinflammatory domain, and promotes sympathetic nervous system activation that impairs optic nerve head perfusion through the ANS/vascular domain. Addressing chronic cortisol elevation therefore has downstream benefits across all other domains.
The ANS/vascular domain is addressed second, with particular priority in NTG presentations where vascular mechanism is primary. Magnesium and Ginkgo biloba constitute the evidence-based first-line intervention pair, with the goal of restoring optic nerve head perfusion pressure and reducing ischemic vulnerability at the critical unmyelinated zone.
The immune/inflammatory domain is addressed third. Microglial activation is reduced through anti-inflammatory support, lutein and zeaxanthin provide dual antioxidant and anti-inflammatory retinal protection, and CB2-mediated cannabinoid neuroprotection is considered where clinically appropriate and legally permissible.
The mitochondrial stack is introduced fourth: nicotinamide (with CD38 inhibitory support in patients with significant inflammatory burden), CoQ10, alpha-lipoic acid, and citicoline. This sequencing reflects the Systems Homeostasis principle that mitochondrial interventions land on a biochemically more receptive system when upstream inflammatory burden, vascular insufficiency, and HPA dysregulation have been addressed first. RGC neuroprotection is a receiver state dependent outcome — the upstream terrain determines the ceiling of the neuroprotective response.
The Formulation Intelligence Engine (FIE) operationalizes this sequencing clinically, mapping patient case data across all seven physiological systems — HPA axis, HPT axis, HPG axis, mitochondrial/metabolic, immune/inflammatory, gut-brain interface, and autonomic nervous system — to identify upstream signaling bottlenecks and sequence interventions accordingly before any compound is introduced.
Conclusion
Glaucoma management focused exclusively on IOP reduction addresses one risk factor while leaving the primary pathological mechanism—RGC apoptosis driven by mitochondrial failure, neuroinflammation, cortisol-mediated trabecular meshwork dysfunction, and autonomic vascular dysregulation—substantially unaddressed. The evidence base for upstream intervention across each of these domains is substantial and growing: nicotinamide and citicoline for mitochondrial neuroprotection, cannabinoid CB2 receptor modulation for neuroinflammatory RGC protection, HPA axis assessment and management for trabecular meshwork GR burden, and magnesium and Ginkgo biloba for ANS/vascular normalization in NTG.
The clinical sequencing of these interventions—HPA terrain first, ANS/vascular second, immune/inflammatory third, mitochondrial stack fourth—reflects a systematic upstream-before-downstream approach that recognizes RGC neuroprotection as receiver state dependent. Establishing the physiological terrain before introducing neuroprotective compounds is not a theoretical preference but a mechanistic requirement if clinical response is to be maximized.
References
- Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901-1911.
- Iwase A, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111(9):1641-1648.
- Williams PA, et al. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science. 2017;355(6326):756-760.
- Parisi V, et al. Cytidine-5′-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology. 1999;106(6):1126-1134.
- Soto I, Howell GR. The complex role of neuroinflammation in glaucoma. Cold Spring Harb Perspect Med. 2014;4(8):a017269.
- Clark AF, Wordinger RJ. The role of steroids in outflow resistance. Exp Eye Res. 2009;88(4):752-759.
- Flammer J, et al. The primary vascular dysregulation syndrome: implications for eye diseases. EPMA J. 2013;4(1):14.
- Celebi S, et al. The effect of oral magnesium therapy on visual field and ocular blood flow in normotensive glaucoma. Eur J Ophthalmol. 2003;13(5):402-406.
- Quaranta L, et al. Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. Ophthalmology. 2003;110(2):359-362.
